摘要
目的:观察清解益肺苗方治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的有效性及安全性。方法:选取60例明确诊断为NSCLCⅢB-Ⅳ期、中医辨证为气阴两虚型患者,研究对象被随机分为对照组30例和治疗组30例。对照组接受吉非替尼片治疗,而治疗组则在此基础上增加清解益肺苗方的辅助疗法。对比两组患者治疗前后中医临床证候疗效、肿瘤近期客观疗效、功能状况、肿瘤标志物、不良反应及安全性。结果:治疗后中医临床证候疗效总有效率治疗组优于对照组,差异有统计学意义(P<0.05);治疗组肿瘤控制率(disease control rate,DCR)优于对照组,差异有统计学意义(P<0.05);治疗组KPS评分高于对照组,血清癌胚抗原(carcinoembryonic antigen,CEA)水平优于对照组,差异有统计学意义(P<0.05);对照组和治疗组皮疹发生情况比较,差异无统计学意义(P>0.05),治疗组腹泻发生情况显著少于对照组,差异有统计学意义(P<0.05);治疗组及对照组治疗后血常规、肝肾功能、心电图等指标未见明显异常。结论:清解益肺苗方治疗NSCLC患者在改善中医临床证候、控制肿瘤生长、提高患者功能状态、降低血清CEA,减轻不良反应方面均优于单用吉非替尼,且较为安全。
Objective:To observe the effectiveness and safety of Qingjie Yifei Miaofang in the treatment of patients with non-small cell lung cancer(NSCLC).Methods:A total of 60 patients with stageⅢB-Ⅳof NSCLC and both deficiency of Qi and Yin in TCM syndrome differentiation were selected and randomly divided into control group(30 cases)and treatment group(30 cases).The patients in the control group were treated with gefitinib tablets,while the patients in the treatment group were treated with Qingjie Yifei Miaofang on the basis of gefitinib tablets.The efficacy of TCM clinical syndrome,short-term objective treatment effect of tumor,functional status,tumor markers,adverse reactions and safety were compared between the two groups before and after treatment.Results:After treatment,the total effective rate of TCM clinical syndrome in the treatment group was better than that in the control group,and the difference was statistically significant(P<0.05).The disease control rate(DCR)of the treatment group were better than those of the control group,and the differences were statistically significant(P<0.05).The KPS score of the treatment group was higher than that of the control group,and the serum carcinoembryonic antigen(CEA)level was better than that of the control group,with the statistical significances(P<0.05).There was no statistical significance in the occurrence of rash between the control group and the treatment group(P>0.05).The incidence of diarrhea in the treatment group was significantly less than that in the control group,and the difference was statistically significant(P<0.05).There were no obvious abnormalities in blood routine,liver and kidney function,electrocardiogram and other indicators after treatment in the treatment group and the control group.Conclusion:Qingjie Yifei Miaofang in the treatment of patients with NSCLC is better than gefitinib alone in improving TCM clinical syndrome,controlling tumor growth,improving functional status,reducing serum CEA,and reducing adverse reactions,and is safer.
作者
龚钤升
方娴娴
李同瑶
谢友良
刘炜
Gong Qiansheng;Fang Xianxian;Li Tongyao;Xie Youliang;Liu Wei(Guizhou University of Traditional Chinese Medicine,Guiyang Guizhou 550000;Guizhou Qianxinan Traditional Chinese Medicine Hospital,Qianxinan Guizhou 562400;Xiangxiang City People's Hospital,Xiangxiang Hunan 411400;Department of Respiratory Medicine of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang Guizhou 550000)
出处
《山西中医药大学学报》
2025年第4期430-435,共6页
Journal of Shanxi University of Chinese Medicine
基金
国家自然科学基金资助项目(82160952)
贵州省科技计划项目(〔2020〕1Y364)。
